Skip to content

Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced NSCLC Read more

  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Advisory Board
    • Program Advisors
  • R & D
    • GT103
    • Platform
    • Pipeline
    • Data Warehouse
    • Computational Biology Program
    • Vaccine Program
  • Investors & Partnering
  • Patients & Families
  • News
    • Press Releases
    • Publications & Presentations
  • Contact Us

News

Press Releases

Grid Therapeutics Closes Series A Financing

Posted on September 20, 2017, in News, Press Releases
Read more

Grid Therapeutics Signs Exclusive License to Develop a Novel Immuno-Oncology Antibody

Posted on August 28, 2017, in News, Press Releases
Read more

Human antibody enhances medication and significantly increases the death of cancer cells

Posted on July 3, 2017August 3, 2017, in News, Press Releases
Read more

Human antibody bolsters cancer drug performance

Posted on July 1, 2017August 3, 2017, in News, Press Releases
Read more

New antibody appears to re-activate immune system in cancer therapy

Posted on June 28, 2017August 3, 2017, in News, Press Releases
Read more

Antibody appears to attack cancer cells, leaving other cells unscathed

Posted on May 5, 2016August 3, 2017, in News, Press Releases
Read more

Researchers develop human-derived antibody that appears to destroy cancer cells

Posted on May 5, 2016August 3, 2017, in News, Press Releases
Read more

This breakthrough cancer treatment could target deadly cells and CURE killer disease

Posted on May 5, 2016August 8, 2017, in News, Press Releases
Read more

Posts navigation

Newer posts
  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Advisory Board
    • Program Advisors
  • R & D
    • GT103
    • Platform
    • Pipeline
    • Data Warehouse
    • Computational Biology Program
    • Vaccine Program
  • Investors & Partnering
  • Patients & Families
  • News
    • Press Releases
    • Publications & Presentations
  • Contact Us
© 2023 Grid Therapeutics. All rights reserved.